Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KEAP1 |
Variant | mutant |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | KEAP1 mutant indicates an unspecified mutation in the KEAP1 gene. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Recruiting | USA | 0 |
NCT05275868 | Phase I | MGY825 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | CHE | 2 |
NCT03872427 | Phase II | Telaglenastat | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | Active, not recruiting | USA | 0 |
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT04250545 | Phase I | Sapanisertib + Telaglenastat | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT06008093 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) | Recruiting | USA | 0 |
NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Terminated | USA | ESP | DEU | 2 |
NCT04564157 | Phase III | Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) | Active, not recruiting | ESP | 0 |
NCT02417701 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | Completed | USA | 0 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT06431633 | Phase II | Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) | Not yet recruiting | ESP | 0 |